BAXTER Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER, and when can generic versions of BAXTER drugs launch?
BAXTER has two hundred and eighteen approved drugs.
There are sixteen US patents protecting BAXTER drugs. There are two tentative approvals on BAXTER drugs.
There are thirty-seven patent family members on BAXTER drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.
Summary for BAXTER
International Patents: | 37 |
US Patents: | 16 |
Tradenames: | 330 |
Ingredients: | 129 |
NDAs: | 218 |
PTAB Cases with BAXTER as patent owner: | See PTAB cases with BAXTER as patent owner |
Drugs and US Patents for BAXTER
Expired US Patents for BAXTER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baxter Hlthcare Corp | ZOSYN IN PLASTIC CONTAINER | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 050750-002 | Feb 24, 1998 | 8,133,883 | ⤷ Try a Trial |
Baxter Hlthcare | EXTRANEAL | icodextrin | SOLUTION;INTRAPERITONEAL | 021321-001 | Dec 20, 2002 | 4,761,237 | ⤷ Try a Trial |
Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-001 | Nov 17, 1995 | 5,213,804 | ⤷ Try a Trial |
Baxter Hlthcare | MESNEX | mesna | INJECTABLE;INTRAVENOUS | 019884-001 | Dec 30, 1988 | 5,696,172 | ⤷ Try a Trial |
Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | 5,013,556 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAXTER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
International Patents for BAXTER Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20110010742 | ⤷ Try a Trial |
Brazil | PI0905080 | ⤷ Try a Trial |
European Patent Office | 4117625 | ⤷ Try a Trial |
Japan | 2017019879 | ⤷ Try a Trial |
Hong Kong | 1219883 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAXTER Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2447254 | 2018015 | Norway | ⤷ Try a Trial | PRODUCT NAME: 2-4-(N-(5,6-DIFENYLPYRAZIN-2- YL)-N- ISOPROPYLAMINO)BUTYLOKSY-N-; REG. NO/DATE: EU/1/15/1083 20160530 |
2666774 | CA 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
1115417 | CA 2006 00018 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCIN |
1304992 | 2013C/060 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506 |
1532149 | C 2012 003 | Romania | ⤷ Try a Trial | PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-IL)-7-BUT-2-INIL-3-METIL-1-(4-METILCHINAZOLIN-2-ILMETIL)3,7-DIHIDROPURIN-2,6-DIONA, ENANTIOMERII SI SARURILE LOR IN SPECIAL LINAGLIPTIN - LINAGLIPTIN, ENANTIOMERIISI SARURILE ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/707/001 - RO EU/1/11/707/011; DATE OF NATIONAL AUTHORISATION: 20110824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/707/001 - EU/1/11/707/011; DATE OF FIRST AUTHORISATION IN EEA: 20110824 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.